ES2663872T3 - Composición inmunogénica o vacuna contra infección o enfermedad bacteriana gramnegativa, por ejemplo, por Neisseria - Google Patents
Composición inmunogénica o vacuna contra infección o enfermedad bacteriana gramnegativa, por ejemplo, por Neisseria Download PDFInfo
- Publication number
- ES2663872T3 ES2663872T3 ES11708450T ES11708450T ES2663872T3 ES 2663872 T3 ES2663872 T3 ES 2663872T3 ES 11708450 T ES11708450 T ES 11708450T ES 11708450 T ES11708450 T ES 11708450T ES 2663872 T3 ES2663872 T3 ES 2663872T3
- Authority
- ES
- Spain
- Prior art keywords
- seq
- antigen
- amino acid
- immune response
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000002163 immunogen Effects 0.000 title abstract 6
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 208000015181 infectious disease Diseases 0.000 title abstract 2
- 208000035143 Bacterial infection Diseases 0.000 title 1
- 241000588653 Neisseria Species 0.000 title 1
- 208000022362 bacterial infectious disease Diseases 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 7
- 108091007433 antigens Proteins 0.000 abstract 7
- 102000036639 antigens Human genes 0.000 abstract 7
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 6
- 230000028993 immune response Effects 0.000 abstract 6
- 239000012634 fragment Substances 0.000 abstract 5
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 108010078791 Carrier Proteins Proteins 0.000 abstract 3
- 101710116435 Outer membrane protein Proteins 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 230000001580 bacterial effect Effects 0.000 abstract 2
- 239000012528 membrane Substances 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 239000011701 zinc Substances 0.000 abstract 1
- 229910052725 zinc Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Una vacuna para su uso en el tratamiento o prevención de una infección o enfermedad por bacterias gramnegativas que comprende: (I) un primer antígeno que es capaz de provocar una respuesta inmune, si es necesario cuando se acopla a una proteína transportadora, cuya respuesta inmune reconoce una proteína de membrana externa de al menos una primera cepa bacteriana gramnegativa, en la que dicha proteína de membrana externa está involucrada en la absorción de zinc extracelular, en la que dicho primer antígeno comprende: a. un polipéptido que tiene al menos el 30 %, al menos el 40%, al menos el 50%, al menos el 60%, al menos el 70%, al menos el 80%, al menos el 90%, al menos el 95%, al menos el 99 % o al menos el 100 % de identidad con la secuencia de aminoácidos de SEQ ID No. 1, o b. un polipéptido que comprende un fragmento inmunogénico de la secuencia de SEQ ID No. 1, en el que dicho fragmento inmunogénico consiste en una secuencia de aminoácidos que tiene 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 30, 40, 50 o más aminoácidos contiguos de SEQ ID No. 1, y (II) un segundo antígeno, en la que dicho segundo antígeno comprende: a. un polipéptido que tiene al menos el 30 %, al menos el 40%, al menos el 50%, al menos el 60%, al menos el 70%, al menos el 80%, al menos el 90%, al menos el 95%, al menos el 99 % o al menos el 100 % de identidad con la secuencia de aminoácidos de SEQ ID No. 50; opcionalmente en la que dicho segundo antígeno es capaz de provocar una respuesta inmune, si es necesario cuando se acopla a una proteína transportadora, cuya respuesta inmune reconoce la secuencia de aminoácidos de SEQ ID NO. 50, o b. un polipéptido que comprende un fragmento inmunogénico de la secuencia de SEQ ID No. 50, en el que dicho fragmento inmunogénico consiste en una secuencia de aminoácidos que tiene 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 30, 40, 50 o más aminoácidos contiguos de la secuencia de SEQ ID No. 50, y en el que dicho fragmento inmunogénico es capaz de provocar una respuesta inmune, si es necesario cuando se acopla a una proteína transportadora, cuya respuesta inmune reconoce la secuencia de aminoácidos de SEQ ID NO. 50, en la que dicha vacuna comprende una preparación de vesícula de membrana externa bacteriana que comprende dicho primer antígeno, opcionalmente en la que la expresión de dicho primer antígeno se regula positivamente en dicha preparación de vesícula de membrana externa.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31295910P | 2010-03-11 | 2010-03-11 | |
PCT/EP2011/053665 WO2011110655A2 (en) | 2010-03-11 | 2011-03-11 | Vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2663872T3 true ES2663872T3 (es) | 2018-04-17 |
Family
ID=44063688
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES11708450T Active ES2663872T3 (es) | 2010-03-11 | 2011-03-11 | Composición inmunogénica o vacuna contra infección o enfermedad bacteriana gramnegativa, por ejemplo, por Neisseria |
Country Status (8)
Country | Link |
---|---|
US (3) | US9365624B2 (es) |
EP (2) | EP2545068B8 (es) |
JP (2) | JP2013522177A (es) |
CN (1) | CN103124737A (es) |
BR (1) | BR112012022800A2 (es) |
CA (1) | CA2792691A1 (es) |
ES (1) | ES2663872T3 (es) |
WO (1) | WO2011110655A2 (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8431136B2 (en) * | 2005-06-27 | 2013-04-30 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
CN103124737A (zh) * | 2010-03-11 | 2013-05-29 | 葛兰素史密丝克莱恩生物有限公司 | 针对革兰氏阴性菌例如奈瑟菌属感染或疾病的免疫原性组合物或疫苗 |
PL2622078T3 (pl) * | 2010-09-28 | 2015-05-29 | Abera Bioscience Ab | Białko fuzyjne dla ekspresji białka wydzielniczego |
US9950282B2 (en) | 2012-03-15 | 2018-04-24 | Flodesign Sonics, Inc. | Electronic configuration and control for acoustic standing wave generation |
US10967298B2 (en) | 2012-03-15 | 2021-04-06 | Flodesign Sonics, Inc. | Driver and control for variable impedence load |
US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
CA2882619A1 (en) | 2012-09-06 | 2014-03-13 | Novartis Ag | Combination vaccines with serogroup b meningococcus and d/t/p |
WO2014074927A1 (en) * | 2012-11-09 | 2014-05-15 | Samuel Bogoch | Methods of identifying, preventing, and treating virulent aleutian mink disease virus using replikin sequences |
PL404229A1 (pl) * | 2013-06-06 | 2014-12-08 | Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością | Wyizolowany immunogenny antygen bakteryjny i jego zastosowanie w profilaktyce i leczeniu zakażeń wywołanych przez Gram-ujemne bakterie |
US20160235837A1 (en) * | 2013-10-16 | 2016-08-18 | Samuel Bogoch | THERAPIES, VACCINES, AND PREDICTIVE METHODS FOR MIDDLE EAST RESPIRATORY SYNDROME VIRUS (MERS CoV) |
CN105939767B (zh) | 2014-01-08 | 2018-04-06 | 弗洛设计声能学公司 | 具有双声电泳腔的声电泳装置 |
US11021699B2 (en) | 2015-04-29 | 2021-06-01 | FioDesign Sonics, Inc. | Separation using angled acoustic waves |
US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
CN105420161B (zh) * | 2015-12-21 | 2018-07-31 | 江苏省农业科学院 | 一种猪胸膜肺炎放线杆菌外膜囊泡的制备方法及其疫苗 |
US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
EP3529347A1 (en) | 2016-10-19 | 2019-08-28 | Flodesign Sonics, Inc. | Affinity cell extraction by acoustics |
AU2018359019A1 (en) * | 2017-11-06 | 2020-04-09 | Ozq Pty Ltd | Vaccine |
AU2018385759B2 (en) | 2017-12-14 | 2021-10-21 | Flodesign Sonics, Inc. | Acoustic transducer driver and controller |
CN112043824A (zh) * | 2020-09-17 | 2020-12-08 | 北京市农林科学院 | 一种降低空肠弯曲菌在鸡肠道定植的疫苗及其制备方法 |
CN113827622B (zh) * | 2021-08-31 | 2023-11-07 | 南方医科大学 | 奇异变形杆菌外膜囊泡在制备预防或治疗骨溶解性疾病药物中的应用 |
CN117180412B (zh) * | 2023-11-06 | 2024-02-02 | 四川大学华西医院 | 一种鲍曼不动杆菌荚膜多糖疫苗及其制备方法 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1069006B (es) | ||||
GB9726398D0 (en) | 1997-12-12 | 1998-02-11 | Isis Innovation | Polypeptide and coding sequences |
GB9808866D0 (en) | 1998-04-24 | 1998-06-24 | Smithkline Beecham Biolog | Novel compounds |
NZ532665A (en) * | 1998-05-01 | 2005-11-25 | Inst Genomic Research | Neisseria meningitidis antigens and compositions |
GB9810276D0 (en) | 1998-05-13 | 1998-07-15 | Smithkline Beecham Biolog | Novel compounds |
GB9818004D0 (en) | 1998-08-18 | 1998-10-14 | Smithkline Beecham Biolog | Novel compounds |
WO2000055327A2 (en) | 1999-03-12 | 2000-09-21 | Smithkline Beecham Biologicals S.A. | Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies |
CA2373236C (en) * | 1999-05-19 | 2014-08-26 | Chiron S.P.A. | Combination neisserial compositions |
EP2975127A1 (en) * | 1999-10-29 | 2016-01-20 | GlaxoSmithKline Biologicals SA | Neisserial antigenic peptides |
GB9928196D0 (en) * | 1999-11-29 | 2000-01-26 | Chiron Spa | Combinations of B, C and other antigens |
US7947291B2 (en) | 2000-01-25 | 2011-05-24 | The University Of Queensland | Modified surface antigen |
GB0011108D0 (en) * | 2000-05-08 | 2000-06-28 | Microscience Ltd | Virulence gene and protein and their use |
CA2493124C (en) * | 2002-08-02 | 2014-04-29 | Glaxosmithkline Biologicals S.A. | Vaccine |
US7628995B2 (en) | 2003-12-23 | 2009-12-08 | Glaxosmithkline Biologicals S.A. | Outer membrane vesicles and uses thereof |
EP1943269A2 (en) * | 2005-10-14 | 2008-07-16 | Intercell AG | Neisseria meningitidis antigens |
ITRM20060328A1 (it) * | 2006-06-21 | 2007-12-22 | Ist Superiore Sanita | Ceppi di salmonella enterica a ridotta patogenicita metodo di preparazione e relativi usi |
GB0816447D0 (en) * | 2008-09-08 | 2008-10-15 | Glaxosmithkline Biolog Sa | Vaccine |
CN103124737A (zh) * | 2010-03-11 | 2013-05-29 | 葛兰素史密丝克莱恩生物有限公司 | 针对革兰氏阴性菌例如奈瑟菌属感染或疾病的免疫原性组合物或疫苗 |
-
2011
- 2011-03-11 CN CN2011800228351A patent/CN103124737A/zh active Pending
- 2011-03-11 CA CA2792691A patent/CA2792691A1/en not_active Abandoned
- 2011-03-11 BR BR112012022800A patent/BR112012022800A2/pt not_active IP Right Cessation
- 2011-03-11 EP EP11708450.9A patent/EP2545068B8/en active Active
- 2011-03-11 WO PCT/EP2011/053665 patent/WO2011110655A2/en active Application Filing
- 2011-03-11 US US13/583,419 patent/US9365624B2/en active Active
- 2011-03-11 JP JP2012556531A patent/JP2013522177A/ja active Pending
- 2011-03-11 ES ES11708450T patent/ES2663872T3/es active Active
- 2011-03-11 EP EP18152692.2A patent/EP3366696A1/en not_active Withdrawn
-
2016
- 2016-04-28 US US15/140,879 patent/US20170080075A1/en not_active Abandoned
- 2016-06-23 JP JP2016124050A patent/JP2016183185A/ja active Pending
-
2018
- 2018-06-18 US US16/011,222 patent/US20190008943A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
BR112012022800A2 (pt) | 2018-05-15 |
EP2545068B8 (en) | 2018-03-21 |
JP2013522177A (ja) | 2013-06-13 |
WO2011110655A3 (en) | 2011-11-03 |
US20130004510A1 (en) | 2013-01-03 |
EP2545068A2 (en) | 2013-01-16 |
JP2016183185A (ja) | 2016-10-20 |
WO2011110655A2 (en) | 2011-09-15 |
EP3366696A1 (en) | 2018-08-29 |
US20190008943A1 (en) | 2019-01-10 |
CN103124737A (zh) | 2013-05-29 |
US9365624B2 (en) | 2016-06-14 |
US20170080075A1 (en) | 2017-03-23 |
EP2545068B1 (en) | 2018-01-24 |
CA2792691A1 (en) | 2011-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2663872T3 (es) | Composición inmunogénica o vacuna contra infección o enfermedad bacteriana gramnegativa, por ejemplo, por Neisseria | |
RU2508126C2 (ru) | Композиции для иммунизации против staphylococcus aureus | |
BR112015022971A2 (pt) | métodos de fabricação para controlar o teor de lisina c-terminal, galactose e ácido siálico em proteínas recombinantes | |
PE20110310A1 (es) | Axmi-115, axmi-113, axmi-005, axmi-163 y axmi-184: proteinas insecticidas | |
Yadav et al. | Characterization of immune response elicited by the recombinant outer membrane protein OmpF of Aeromonas hydrophila, a potential vaccine candidate in murine model | |
BR112012018951C8 (pt) | anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica | |
JP2012523246A5 (es) | ||
PE20121685A1 (es) | Antigeno ndv recombinante y usos del mismo | |
SI2280721T1 (en) | IMUNOTHERAPY BASED ON INDOLEAMINE 2,3-DIOXYGENESIS | |
NZ701881A (en) | Vaccines for hsv-2 | |
BRPI0707300B8 (pt) | vacina contra vírion influenza dividido ou antígeno de superfície purificado e método para a preparação de uma composição imunogênica | |
AR068507A1 (es) | Construcciones vector fluorocarbonado-antigeno para el suministro de antigenos ifluenza | |
ES2637617T3 (es) | Método para mejorar el rendimiento de granos y promover el crecimiento de plantas | |
BR112015002131A8 (pt) | Vírus vaccinia ankara modificado (mva) recombinante, composição farmacêutica e uso do referido mva recombinante | |
GB0722105D0 (en) | Antigens | |
BR112016016103A2 (pt) | Composição de antígenos micobacterianos | |
RU2015106916A (ru) | Полипептиды clostridium difficile в виде вакцины | |
CN106164090A (zh) | TRAIL穿膜肽样突变体MuR6、制备方法及应用 | |
NZ596501A (en) | Casb7439 constructs | |
WO2012009774A3 (pt) | Microrganismos recombinantes, métodos de preparação de linhagens vacinais, antígenos, composições vacinais vetorizadas, seus usos, anticorpos, kit de diagnóstico e métodos de tratamento e/ou profilaxia | |
WO2012036391A3 (ko) | 돼지 써코바이러스2(pcv2) 유전자의 표면발현용 벡터 및 이로 형질전환된 살모넬라 백신 균주 | |
PE20121553A1 (es) | Uso de una fuente de l3 y/o l5 como vacuna o como diagnostico para una efermedad parasitaria | |
BR112015013625A2 (pt) | adjuvante de vacinação, preparação e vacinas contendo o mesmo | |
NZ603854A (en) | West nile virus vaccine | |
AR088176A1 (es) | Secuencias de aminoacidos para el control de patogenos |